Pre-CAR Blinatumomab Is Associated with Increased Post-CD19 CAR Relapse and Decreased Event Free Survival
Agne Taraseviciute(Seattle Children's Hospital), Nirali N. Shah(National Institutes of Health), Lee Chen(Children's Hospital of Philadelphia), Susan R. Rheingold(Children's Hospital of Philadelphia), Deepa Bhojwani(St. Jude Children's Research Hospital), Bonnie Yates(National Institutes of Health), Perry Chung(Children's Hospital of Philadelphia), Lia Gore(Children's Hospital Colorado), Adam J. Lamble(Seattle Children's Hospital), Seth M. Steinberg(National Institutes of Health), Jennifer Sheppard(Southwestern Medical Center), Rebecca Gardner(Seattle Children's Hospital), Theodore W. Laetsch(Children's Hospital of Philadelphia), Regina M. Myers(Children's Hospital of Philadelphia), Michael A. Pulsipher(Primary Children's Hospital), Colleen Annesley(Unknown), Patrick A. Brown(Haemonetics (United States))
Cited by 24
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
|Journal of Hepatology|2016|817
Comprehensive Analysis of Hypermutation in Human Cancer
|Cell|2017|795